Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch

Dow Jones

08/15

By Nicholas G. Miller

Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage.

The stock is up 10% to $7.23 and is up 44% over the past 12 months.

The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year.

Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers.

Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

August 14, 2025 14:48 ET (18:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559962969"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559962969\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559962969?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 02:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559962969","market":"sh","top_or_hot":-1,"title":"Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n</p>\n<p>\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n</p>\n<p>\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n</p>\n<p>\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n</p>\n<p>\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 14:48 ET (18:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-15 02:48</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n</p>\n<p>\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n</p>\n<p>\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n</p>\n<p>\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n</p>\n<p>\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 14:48 ET (18:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABEO","symbol_name":"Abeona Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2559962969","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559962969","pubTimestamp":1755197280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage.The stock is up 10% to $7.23 and is up 44% over the past 12 months.The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year.Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers.Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABEO":"Abeona Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Abeona Therapeutics股价因第二季度净值上涨和药物上市而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABEO":1},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n\n\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n\n\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n\n\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n\n\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2025 14:48 ET (18:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}